Insmed Stock Price, News & Analysis (NASDAQ:INSM)

$25.87 +1.46 (+5.98 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$25.87
Today's Range$21.90 - $25.91
52-Week Range$11.49 - $33.94
Volume2.51 million shs
Average Volume831,829 shs
Market Capitalization$1.87 billion
P/E Ratio-8.32
Dividend YieldN/A
Beta1.09

About Insmed (NASDAQ:INSM)

Insmed logoInsmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.

Receive INSM News and Ratings via Email

Sign-up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INSM
CUSIPN/A
Phone908-977-9900

Debt

Debt-to-Equity Ratio0.13%
Current Ratio15.21%
Quick Ratio15.21%

Price-To-Earnings

Trailing P/E Ratio-8.31830122732724
Forward P/E Ratio-9.69
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.50 per share
Price / Book10.35

Profitability

Trailing EPS($3.11)
Net Income$-176,270,000.00
Net MarginsN/A
Return on Equity-100.23%
Return on Assets-70.48%

Miscellaneous

Employees161
Outstanding Shares76,610,000

Insmed (NASDAQ:INSM) Frequently Asked Questions

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) released its quarterly earnings results on Friday, February, 23rd. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.18. View Insmed's Earnings History.

Where is Insmed's stock going? Where will Insmed's stock price be in 2018?

8 brokers have issued 1-year target prices for Insmed's stock. Their forecasts range from $17.00 to $54.00. On average, they expect Insmed's stock price to reach $37.25 in the next twelve months. View Analyst Ratings for Insmed.

Who are some of Insmed's key competitors?

Who are Insmed's key executives?

Insmed's management team includes the folowing people:

  • William H. Lewis, President, Chief Executive Officer, Director (Age 48)
  • Paolo Tombesi, Chief Financial Officer (Age 54)
  • S. Nicole Schaeffer, Senior Vice President- Human Resource and Corporate Services (Age 48)
  • Walter Perkins Ph.D., Chief Technology Officer
  • Eugene Jeffrey Sullivan M.D., Chief Product Strategy Officer and Chief Scientific Officer (Age 52)
  • Christine A. Pellizzari, General Counsel, Corporate Secretary (Age 49)
  • Roger Adsett, Chief Commercial Officer (Age 48)
  • Paul Streck, Chief Medical Officer (Age 54)
  • Donald J. Hayden Jr., Non-Executive Chairman of the Board (Age 61)
  • Alfred F. Altomari, Independent Director (Age 58)

Who owns Insmed stock?

Insmed's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.22%), Palo Alto Investors LLC (8.36%), Redmile Group LLC (2.94%), Emerald Advisers Inc. PA (1.12%), Geode Capital Management LLC (0.90%) and Rock Springs Capital Management LP (0.80%). Company insiders that own Insmed stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden Jr, Melvin Md Sharoky, Myrtle S Potter and Orlov S Nicole Schaeffer. View Institutional Ownership Trends for Insmed.

Who sold Insmed stock? Who is selling Insmed stock?

Insmed's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, University of Notre Dame DU Lac, Endurant Capital Management LP, Goldman Sachs Group Inc., C WorldWide Group Holding A S, Two Sigma Investments LP, HBK Investments L P and Deutsche Bank AG. Company insiders that have sold Insmed company stock in the last year include Donald J Hayden Jr and Melvin Md Sharoky. View Insider Buying and Selling for Insmed.

Who bought Insmed stock? Who is buying Insmed stock?

Insmed's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Nexthera Capital LP, Redmile Group LLC, Palo Alto Investors LLC, Guggenheim Capital LLC, Alps Advisors Inc., MetLife Investment Advisors LLC and State of Wisconsin Investment Board. View Insider Buying and Selling for Insmed.

How do I buy Insmed stock?

Shares of Insmed can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insmed's stock price today?

One share of Insmed stock can currently be purchased for approximately $25.87.

How big of a company is Insmed?

Insmed has a market capitalization of $1.87 billion. The biopharmaceutical company earns $-176,270,000.00 in net income (profit) each year or ($3.11) on an earnings per share basis. Insmed employs 161 workers across the globe.

How can I contact Insmed?

Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]


MarketBeat Community Rating for Insmed (INSM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  195 (Vote Underperform)
Total Votes:  417
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Insmed (NASDAQ:INSM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.862.80
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $37.25$37.25$36.71$23.75
Price Target Upside: 25.97% upside25.97% upside22.34% upside102.82% upside

Insmed (NASDAQ:INSM) Consensus Price Target History

Price Target History for Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2018Credit Suisse GroupInitiated CoverageNeutral -> Neutral$31.00MediumView Rating Details
1/4/2018HC WainwrightReiterated RatingBuy$35.00MediumView Rating Details
1/4/2018Robert W. BairdReiterated RatingOutperform -> Positive$32.00 -> $42.00HighView Rating Details
11/3/2017CowenReiterated RatingBuy$54.00N/AView Rating Details
9/6/2017Stifel NicolausReiterated RatingBuy$27.00 -> $43.00HighView Rating Details
9/5/2017Leerink SwannBoost Price TargetOutperform$27.00 -> $36.00HighView Rating Details
9/5/2017Evercore ISIBoost Price TargetOutperform -> Outperform$28.00 -> $40.00HighView Rating Details
6/11/2017CitigroupReiterated RatingNeutral$14.00 -> $17.00HighView Rating Details
8/21/2016Piper Jaffray CompaniesSet Price TargetBuy$24.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Insmed (NASDAQ:INSM) Earnings History and Estimates Chart

Earnings by Quarter for Insmed (NASDAQ:INSM)

Insmed (NASDAQ INSM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2018Q4 2017($0.67)($0.85)ViewN/AView Earnings Details
11/2/2017Q3 2017($0.69)($0.69)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.63)($0.72)ViewListenView Earnings Details
5/3/2017Q1 2017($0.60)($0.60)$0.30 millionViewListenView Earnings Details
2/23/2017Q316($0.89)($1.10)$0.30 millionViewN/AView Earnings Details
11/3/2016Q216($0.59)($0.61)$0.10 millionViewN/AView Earnings Details
8/4/2016Q2($0.56)($0.59)ViewN/AView Earnings Details
5/5/2016Q1($0.56)($0.54)ViewN/AView Earnings Details
2/25/2016Q415($0.49)($0.51)ViewN/AView Earnings Details
11/6/2015Q315($0.48)($0.50)ViewN/AView Earnings Details
8/6/2015Q2($0.48)($0.47)ViewN/AView Earnings Details
5/7/2015Q115($0.49)($0.55)ViewN/AView Earnings Details
2/27/2015Q414($0.57)($0.36)ViewN/AView Earnings Details
11/6/2014Q314($0.51)($0.54)ViewN/AView Earnings Details
8/6/2014Q214($0.50)($0.59)ViewN/AView Earnings Details
5/8/2014Q114($0.39)($0.36)ViewN/AView Earnings Details
3/6/2014Q413($0.45)($0.41)ViewN/AView Earnings Details
11/5/2013Q313($0.41)($0.46)ViewListenView Earnings Details
8/6/2013Q2 2013($0.32)($0.28)$5.38 million$11.50 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.46)($0.43)ViewListenView Earnings Details
3/18/2013Q4 2012($0.31)($0.49)ViewN/AView Earnings Details
11/7/2012Q312($0.42)($0.38)ViewN/AView Earnings Details
8/7/2012Q2 2012($0.31)($0.39)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.34)($0.28)ViewN/AView Earnings Details
3/13/2012Q4 2011($0.38)($0.28)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.28)($0.35)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.33)($0.40)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.32)($0.37)ViewN/AView Earnings Details
3/10/2011Q4 2010($0.10)($0.48)ViewN/AView Earnings Details
11/3/2010Q3 2010($0.03)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.03)ViewN/AView Earnings Details
5/6/2010Q1 2010$0.01ViewN/AView Earnings Details
3/15/2010Q4 2009$0.10ViewN/AView Earnings Details
11/6/2009Q3 2009($0.01)ViewN/AView Earnings Details
8/13/2009Q2 2009($0.13)ViewN/AView Earnings Details
5/13/2009Q1 2009$2.83ViewN/AView Earnings Details
3/11/2009Q4 2008($0.32)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.18)ViewN/AView Earnings Details
8/8/2008Q2 2008($0.38)ViewN/AView Earnings Details
5/8/2008Q1 2008($0.40)ViewN/AView Earnings Details
3/4/2008Q4 2007($0.30)($0.27)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Insmed (NASDAQ:INSM) Earnings Estimates

2018 EPS Consensus Estimate: ($2.39)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.58)($0.58)($0.58)
Q2 20181($0.60)($0.60)($0.60)
Q3 20181($0.60)($0.60)($0.60)
Q4 20181($0.61)($0.61)($0.61)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Insmed (NASDAQ:INSM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insmed (NASDAQ INSM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.03%
Institutional Ownership Percentage: 96.30%
Insider Trades by Quarter for Insmed (NASDAQ:INSM)
Insider Trades by Quarter for Insmed (NASDAQ:INSM)

Insmed (NASDAQ INSM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/14/2017Donald J Hayden JrDirectorSell15,000$32.50$487,500.0071,131View SEC Filing  
9/7/2017Donald J Hayden JrDirectorSell45,000$29.67$1,335,150.0071,131View SEC Filing  
9/6/2017Melvin Md SharokyDirectorSell50,000$27.37$1,368,500.00View SEC Filing  
5/31/2017Christine A PellizzariGeneral CounselBuy10,000$15.14$151,400.0027,300View SEC Filing  
12/15/2016Christine A PellizzariGeneral CounselBuy20,000$12.81$256,200.0010,000View SEC Filing  
12/14/2016Myrtle S PotterDirectorSell6,466$12.79$82,700.145,000View SEC Filing  
11/14/2016Andrew T DrechslerCFOSell45,000$14.67$660,150.0020,000View SEC Filing  
11/9/2016Orlov S Nicole SchaefferSVPSell68,774$11.95$821,849.3037,500View SEC Filing  
2/1/2016William LewisCEOBuy50,000$13.34$667,000.0096,972View SEC Filing  
9/2/2015Donald J. Hayden, Jr.DirectorSell25,000$24.06$601,500.0036,687View SEC Filing  
5/12/2015Mark QuigleyVPSell18,750$22.07$413,812.50View SEC Filing  
8/13/2014Melvin Md SharokyDirectorBuy88,889$11.25$1,000,001.25View SEC Filing  
11/1/2013William LewisCEOBuy5,233$14.28$74,727.24View SEC Filing  
7/22/2013Fmr LlcInsiderSell158,758$12.02$1,908,271.16View SEC Filing  
7/18/2013Fmr LlcInsiderSell310,227$11.49$3,564,508.23View SEC Filing  
7/15/2013Fmr LlcInsiderSell161,531$10.79$1,742,919.49View SEC Filing  
7/9/2013Fmr LlcInsiderSell146,599$10.01$1,467,455.99View SEC Filing  
7/3/2013Fmr LlcInsiderSell365,779$9.96$3,643,158.84View SEC Filing  
7/1/2013William LewisCEOBuy7,585$9.83$74,560.55View SEC Filing  
6/24/2013Fmr LlcInsiderSell50,000$12.00$600,000.00View SEC Filing  
6/20/2013Fmr LlcInsiderSell143,088$12.24$1,751,397.12View SEC Filing  
6/12/2013Fmr LlcInsiderSell85,758$13.00$1,114,854.00View SEC Filing  
6/6/2013Fmr LlcInsiderSell130,557$12.85$1,677,657.45View SEC Filing  
4/1/2013William LewisCEOBuy9,816$7.58$74,405.28View SEC Filing  
1/9/2013William LewisCEOBuy10,770$6.90$74,313.00View SEC Filing  
12/3/2012William LewisCEOBuy13,568$7.36$99,860.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Insmed (NASDAQ INSM) News Headlines

Source:
DateHeadline
Insmed (INSM) Posts Quarterly  Earnings Results, Misses Estimates By $0.18 EPSInsmed (INSM) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPS
www.americanbankingnews.com - February 24 at 10:52 AM
Insmed Breaks Below 200-Day Moving Average - Notable for INSMInsmed Breaks Below 200-Day Moving Average - Notable for INSM
www.nasdaq.com - February 23 at 4:54 PM
Insmed Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateInsmed Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - February 23 at 9:24 AM
Insmed Target of Unusually High Options Trading (INSM)Insmed Target of Unusually High Options Trading (INSM)
www.americanbankingnews.com - February 23 at 8:26 AM
Stock Traders Purchase High Volume of Insmed Put Options (INSM)Stock Traders Purchase High Volume of Insmed Put Options (INSM)
www.americanbankingnews.com - February 22 at 7:44 AM
Insmed (INSM) Downgraded by BidaskClubInsmed (INSM) Downgraded by BidaskClub
www.americanbankingnews.com - February 18 at 2:18 PM
Insmed Incorporated (INSM) Receives Average Rating of "Buy" from AnalystsInsmed Incorporated (INSM) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 17 at 1:48 AM
Insmed to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Friday, February 23, 2018Insmed to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Friday, February 23, 2018
finance.yahoo.com - February 15 at 8:46 AM
Insmed (INSM) and GW Pharmaceuticals PLC- (GWPH) Head-To-Head ContrastInsmed (INSM) and GW Pharmaceuticals PLC- (GWPH) Head-To-Head Contrast
www.americanbankingnews.com - February 14 at 7:18 PM
Insmed (INSM) to Release Quarterly Earnings on WednesdayInsmed (INSM) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 14 at 2:20 AM
 Brokerages Expect Insmed Incorporated (INSM) to Post -$0.67 Earnings Per Share Brokerages Expect Insmed Incorporated (INSM) to Post -$0.67 Earnings Per Share
www.americanbankingnews.com - February 11 at 5:14 AM
Insmed to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceInsmed to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 8:55 AM
Insmed Sees Unusually Large Options Volume (INSM)Insmed Sees Unusually Large Options Volume (INSM)
www.americanbankingnews.com - February 3 at 2:44 AM
Zacks Investment Research Downgrades Insmed (INSM) to HoldZacks Investment Research Downgrades Insmed (INSM) to Hold
www.americanbankingnews.com - January 28 at 10:22 PM
Comparing Insmed (INSM) and Its CompetitorsComparing Insmed (INSM) and Its Competitors
www.americanbankingnews.com - January 28 at 1:18 PM
Zacks Investment Research Upgrades Insmed (INSM) to BuyZacks Investment Research Upgrades Insmed (INSM) to Buy
www.americanbankingnews.com - January 28 at 10:34 AM
Insmed (INSM) Downgraded by BidaskClub to SellInsmed (INSM) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - January 27 at 3:24 PM
Critical Comparison: Insmed (INSM) & Its PeersCritical Comparison: Insmed (INSM) & Its Peers
www.americanbankingnews.com - January 25 at 5:16 PM
BRIEF-Insmed Prices Public Offering Of $400 Mln Principal Amount Of Its Convertible Senior NotesBRIEF-Insmed Prices Public Offering Of $400 Mln Principal Amount Of Its Convertible Senior Notes
www.reuters.com - January 24 at 9:35 AM
Insmed Incorporated (INSM) Given Average Rating of "Buy" by BrokeragesInsmed Incorporated (INSM) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 23 at 1:40 AM
BRIEF-Insmed Announces Proposed Public Offering Of Convertible Senior NotesBRIEF-Insmed Announces Proposed Public Offering Of Convertible Senior Notes
www.reuters.com - January 22 at 5:49 PM
Insmed Announces Proposed Public Offering of Convertible Senior NotesInsmed Announces Proposed Public Offering of Convertible Senior Notes
finance.yahoo.com - January 22 at 5:49 PM
Analyzing Aldeyra Therapeutics (ALDX) and Insmed (INSM)Analyzing Aldeyra Therapeutics (ALDX) and Insmed (INSM)
www.americanbankingnews.com - January 17 at 7:10 PM
Credit Suisse Group Initiates Coverage on Insmed (INSM)Credit Suisse Group Initiates Coverage on Insmed (INSM)
www.americanbankingnews.com - January 17 at 5:24 PM
Insmed (INSM) Stock Rating Lowered by Zacks Investment ResearchInsmed (INSM) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 14 at 8:10 PM
Head to Head Contrast: Insmed (INSM) & Its CompetitorsHead to Head Contrast: Insmed (INSM) & Its Competitors
www.americanbankingnews.com - January 13 at 9:26 AM
Insmed Incorporated (INSM) Sees Significant Increase in Short InterestInsmed Incorporated (INSM) Sees Significant Increase in Short Interest
www.americanbankingnews.com - January 12 at 3:14 AM
Equities Analysts Issue Forecasts for Insmed Incorporateds Q1 2018 Earnings (INSM)Equities Analysts Issue Forecasts for Insmed Incorporated's Q1 2018 Earnings (INSM)
www.americanbankingnews.com - January 8 at 5:02 AM
With A -40.65% Earnings Drop Lately, Did Insmed Incorporated (NASDAQ:INSM) Underperform Its Industry?With A -40.65% Earnings Drop Lately, Did Insmed Incorporated (NASDAQ:INSM) Underperform Its Industry?
finance.yahoo.com - January 5 at 3:28 PM
Insmeds (INSM) "Buy" Rating Reiterated at HC WainwrightInsmed's (INSM) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - January 4 at 1:28 PM
Insmed Announces Additional Data from ALIS (Amikacin Liposome Inhalation Suspension) Phase 3 Clinical Program for Adult Patients with Treatment Refractory NTM Lung Disease Caused by MAC and Reports Progress with Commercial PreparationsInsmed Announces Additional Data from ALIS (Amikacin Liposome Inhalation Suspension) Phase 3 Clinical Program for Adult Patients with Treatment Refractory NTM Lung Disease Caused by MAC and Reports Progress with Commercial Preparations
finance.yahoo.com - January 4 at 8:55 AM
Insmeds (INSM) Positive Rating Reaffirmed at Robert W. BairdInsmed's (INSM) Positive Rating Reaffirmed at Robert W. Baird
www.americanbankingnews.com - January 4 at 8:20 AM
Insmed Target of Unusually Large Options Trading (INSM)Insmed Target of Unusually Large Options Trading (INSM)
www.americanbankingnews.com - January 4 at 4:38 AM
Head to Head Analysis: Insmed (INSM) versus Its RivalsHead to Head Analysis: Insmed (INSM) versus Its Rivals
www.americanbankingnews.com - January 3 at 7:06 PM
How Financially Strong Is Insmed Incorporated (NASDAQ:INSM)?How Financially Strong Is Insmed Incorporated (NASDAQ:INSM)?
finance.yahoo.com - December 29 at 11:01 AM
Insmed (INSM) Upgraded to "Hold" by BidaskClubInsmed (INSM) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - December 23 at 1:28 PM
-$0.66 Earnings Per Share Expected for Insmed Incorporated (INSM) This Quarter-$0.66 Earnings Per Share Expected for Insmed Incorporated (INSM) This Quarter
www.americanbankingnews.com - December 22 at 7:25 PM
Commit To Buy Insmed At $15, Earn 13.7% Using OptionsCommit To Buy Insmed At $15, Earn 13.7% Using Options
www.nasdaq.com - December 21 at 3:29 PM
Barrons After Hours: Insmed Soars, Western Digital Jumps, VeriFone SlumpsBarron's After Hours: Insmed Soars, Western Digital Jumps, VeriFone Slumps
finance.yahoo.com - December 13 at 8:49 AM
 Brokerages Expect Insmed, Inc. (INSM) to Announce -$0.66 EPS Brokerages Expect Insmed, Inc. (INSM) to Announce -$0.66 EPS
www.americanbankingnews.com - December 4 at 11:26 PM
Insmed, Inc. (INSM) Receives Consensus Recommendation of "Hold" from BrokeragesInsmed, Inc. (INSM) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 4 at 1:56 AM
Today’s Research Reports on Stocks to Watch: Horizon Pharma and Insmed IncorporatedToday’s Research Reports on Stocks to Watch: Horizon Pharma and Insmed Incorporated
finance.yahoo.com - December 1 at 11:45 AM
Insmed, Inc. Fundamental Analysis : November 30, 2017Insmed, Inc. Fundamental Analysis : November 30, 2017
finance.yahoo.com - December 1 at 11:45 AM
Insmed to Present at the Nasdaq 37th Annual Investor ConferenceInsmed to Present at the Nasdaq 37th Annual Investor Conference
finance.yahoo.com - November 28 at 9:37 AM
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - November 23 at 2:24 AM
Today’s Research Reports on Stocks to Watch: Juno Therapeutics and Insmed IncorporatedToday’s Research Reports on Stocks to Watch: Juno Therapeutics and Insmed Incorporated
finance.yahoo.com - November 17 at 7:01 AM
Donald J. Hayden, Jr. Sells 15,000 Shares of Insmed, Inc. (INSM) StockDonald J. Hayden, Jr. Sells 15,000 Shares of Insmed, Inc. (INSM) Stock
www.americanbankingnews.com - November 16 at 4:24 PM
Technical Reports on Biotech Equities -- ImmunoGen, Incyte, Infinity Pharma, and Insmed - PR Newswire (press release)Technical Reports on Biotech Equities -- ImmunoGen, Incyte, Infinity Pharma, and Insmed - PR Newswire (press release)
www.prnewswire.com - November 11 at 12:38 PM
Implied Volatility Surging for Insmed Incorporated (INSM) Stock OptionsImplied Volatility Surging for Insmed Incorporated (INSM) Stock Options
finance.yahoo.com - November 11 at 12:38 PM
3 Companies Spearheading the Antibiotics Space in 20183 Companies Spearheading the Antibiotics Space in 2018
finance.yahoo.com - November 11 at 12:38 PM

SEC Filings

Insmed (NASDAQ:INSM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Insmed (NASDAQ:INSM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Insmed (NASDAQ INSM) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.